Diabetes-Renal Dual-Adapted ONS is estimated to account for 48.3% of Product Type demand in 2026, while Stage 3 represents 51.5% of CKD Stage demand and RTD products hold 38.4% of Product Form demand. The market was valued at USD 310.3 million in 2025, with demand shaped by the need to manage glucose exposure and renal nutrient restrictions within the same nutrition plan.